The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

For many years, astrocytes were seen as simple support cells in the brain. Today, that picture is changing fast.

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to ...

Despite advances, the roles of genetics and microenvironment in CLL are not fully understood, and curative treatments may hinge on a dual approach targeting both.

Combination therapy of osimertinib and datopotamab deruxtecan shows promising efficacy in advanced NSCLC, warranting further ...

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related deaths worldwide ...

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

Night shifts may be unconventional, but in the fast-paced society we live in, companies often keep day and night shifts to ...